April 27th 2024
Targeted therapies and immunotherapies across the ovarian, endometrial, and cervical cancers landscape play expanded roles, according to Ritu Salani, MD, MBA.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Rucaparib Maintenance Improves PFS in Recurrent Ovarian Cancer Regardless of Prior Chemo Regimens
December 20th 2018According to findings from a subgroup analysis of the phase III ARIEL3 study presented at the 2018 ESMO Congress, the PARP inhibitor rucaparib (Rubraca) improved progression-free survival as a maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer compared to placebo, despite the number prior of chemotherapy regimens.
Read More
FDA Approves Olaparib as Frontline Maintenance Therapy in Ovarian Cancer
December 20th 2018Olaparib has been approved by the FDA as a maintenance therapy for patients with deleterious or suspected deleterious germline or somatic <em>BRCA</em>-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to frontline platinum-based chemotherapy, as approved by an FDA-approved companion diagnostic assay.
Read More
Rischin Discusses Cemiplimab Potential in Cervical Cancer
December 18th 2018Danny Rischin, MD, discusses the potential of cemiplimab in patients with cervical cancer. The PD-1 inhibitor cemiplimab demonstrated antitumor activity and a tolerable safety profile as a monotherapy and in combination with hypofractionated radiotherapy for the treatment of patients with metastatic or recurrent cervical cancer.
Read More
Surgical Approaches to Gynecologic Cancers
December 18th 2018Paul H. Sugarbaker, MD, FACS, FRCS, chief of the peritoneal surface malignancy program and director of the Center for Gastrointestinal Malignancies at Medstar Washington Hospital Center, discusses how surgical approaches have evolved in gynecologic cancers.
Watch
EU Panel Recommends Approval of Maintenance Rucaparib for Ovarian Cancer
December 18th 2018Based on findings from the phase III ARIEL3 trial, the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending an expanded approval for single-agent rucaparib as a maintenance treatment for adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
Read More
O'Malley Discusses the Role of Bevacizumab Maintenance in an Ovarian Cancer Case Study
December 7th 2018During a <em>Targeted Oncology</em> live case-based peer perspectives presentation, David O’Malley, reviewed the treatment considerations and decisions he makes when treating patients with ovarian cancer. O’Malley explained to the group the factors that go into treatment decision making during the meeting based on a case scenario of a patient with high-grade serous carcinoma.
Read More
I-O Combo of Checkpoint Inhibitor With CAR T-Cell Therapy Shows Promise in Relapsed B-Cell ALL
December 3rd 2018According to results from a small clinical study, checkpoint inhibitors in combination with chimeric antigen receptor T-cell therapy showed promise for improving CAR T-cell persistance in some patients with relapsed B-cell acute lymphoblastic leukemia. <br />
Read More
Risk of Relapse Reduced With HCT Following CAR T-Cell Therapy in ALL
December 2nd 2018Patients with acute lymphoblastic leukemia saw a reduction in the risk for recurrence after receiving a stem cell transplant for the first time following treatment with CD19 chimeric antigen receptor T-cell therapy.
Read More
Avelumab Falls Short of PFS, OS Improvement in Phase III Ovarian Cancer Trial
November 20th 2018According to the findings from phase III JAVELIN Ovarian 200 trial, avelumab either alone or in combination with pegylated liposomal doxorubicin did not induce a statistically significant improvement in overall survival or progression-free survival in patients with platinum–resistant/refractory ovarian cancer compared to PLD monotherapy.
Read More
Olaparib Suitable For Long-term Maintenance in Recurrent Ovarian Cancer
November 14th 2018The side effect profile of olaparib tablets and the low rate of treatment discontinuation make it suitable for maintenance treatment for patients with platinum-sensitive recurrent ovarian cancer, according to safety assessments from the SOLO-2 trial.
Read More
Olaparib Granted Priority Review by FDA for Frontline Maintenance in Ovarian Cancer
November 12th 2018Based on data from the phase III SOLO-1 trial, a supplemental new drug application for olaparib tablets has been granted a priority review by the FDA for use as a maintenance therapy in patients with newly-diagnosed,<em> BRCA</em>-positive advanced ovarian cancer who achieved a complete or partial response to standard frontline platinum-based chemotherapy.
Read More
Campos Highlights Biggest Advancement in Ovarian Cancer This Year
November 8th 2018Susana M. Campos, MD, discusses her thoughts on the biggest advancements in ovarian cancer in 2018. PARP inhibitors are great at putting these patients in remission; however, the challenge with this lies in keeping them in remission.
Watch
Rates of Niraparib-Related AEs Markedly Lower in Real World Compared With Clinical Trial
November 7th 2018The rate of the 3 most common adverse events reported by US patients on niraparib who were started on 200 mg/day in real-world clinical practice is markedly less than the rate of AEs experienced by those enrolled in the pivotal phase III ENGOT-OV6/NOVA trial, in which patients were started at a 300-mg daily dose of niraparib, according to data presented at the 2018 ESMO Congress.
Read More
Lurbinectedin Shows No PFS Improvement in Platinum-Resistant Ovarian Cancer
November 6th 2018Lurbinectedin did not improve progression-free survival over pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer, according to results of the phase III CORAIL trial.
Read More
Despite Advances, Interpreting Data From Genomics and Precision Medicine Lags
October 25th 2018I think one of the most important advancements in biomedical technology that has improved our understanding of the complexities of cancer is the ability to sequence the cancer genome for any individual patient, in a rapid and cost-effective manner, to help us make treatment decisions in the clinic.
Read More
QUADRA Data Support Use of Niraparib in Later Lines of Therapy for Relapsed Ovarian Cancer
October 25th 2018Data from a posthoc analysis of the phase II QUADRA trial support the use of niraparib in later lines of therapy in patients with relapsed ovarian cancer who have <em>BRCA</em> mutations, said Kathleen N. Moore, lead investigator of the trial. According to findings reported at the 2018 ESMO Annual Congress, when used in the fourth line or later, niraparib exhibited an overall response rate of approximately 30% in this subset of patients.
Read More
Pegylated Doxorubicin Added to Bevacizumab and Carboplatin Extends PFS in Recurrent Ovarian Cancer
October 24th 2018As an add-on to bevacizumab, carboplatin plus pegylated liposomal doxorubicin significantly extended progression-free survival compared with carboplatin and gemcitabine in patients with recurrent ovarian cancer whose first disease recurrence was >6 months after first-line platinum-based chemotherapy.
Read More
Financial Advocacy Grows Under the Value-Based System
October 24th 2018Groundbreaking developments in cancer therapies can change lives, extending survival and sending patients who previously thought their chances were slim into remission. But these therapies come at a cost, and many patients reel at the prospect of heavy financial burdens. To help patients and programs meet the challenges of affording cancer treatments, community cancer centers are expanding the role of financial advocates in their organizations.
Read More
ACCC President Reignites Resilience in Oncology Caregivers
October 23rd 2018Thomas A. Gallo, MS, MDA, president of the Association of Community Cancer Centers, discusses his mission as president to “reflect, renew, and reignite” in order to create a more resilient oncology team for the community.
Watch
Larotrectinib Induces 80% ORR in Advanced NTRK+ Solid Tumors
October 22nd 2018Larotrectinib induced an objective response rate of 80% in patients with advanced solid tumors who harbored <em>NTRK </em>gene fusions, according to results pooled from 3 small trials of the TRK inhibitor. Results were presented during the 2018 ESMO Congress.
Read More
CMS Tackles Drug Prices, But What Does This Mean for Patient Care Access?
October 19th 2018Rising prescription drug prices continue to add to the burden of paying for quality healthcare. In an effort to confront such costs, the Centers for Medicare & Medicaid Services has rescinded a prohibition on step therapy for Medicare Advantage plans. But some contend such a policy will reduce patient access to optimal medication.
Read More